【摘要】 目的探讨IL-21水平在预测干扰素（IFN）治疗慢性乙型肝炎（CHB）疗效中的价值。方法 69例HBeAg阳性CHB患者接受IFN治疗48周。ELISA法检测治疗前和治疗12、24、36、48周外周血清IL-21水平,化学发光微粒子免疫检测法定量检测血清HBVM,荧光定量PCR检测血清HBV DNA水平。结果治疗48周时,22例（31.9%）为完全应答（CR）状态,出现HBeAg血清学转换,且HBV DNA<500IU/ml;其余47例（68.1%）为非完全应答（NCR）状态。CR组基线血清IL-21水平高于NCR组（P<0.05）。基线IL-21≥110pg/ml对CR的预测价值达到66.7%;其中,IL-21≥110pg/ml,且HBsAg定量≤3.84log₁₀IU/ml的CHB患者中80.0%能够实现CR。结论治疗前血清IL-21高表达的HBeAg阳性CHB患者预示IFN治疗效果较好。更多还原

【Abstract】 Objective To explore the role of serum IL-21 levels in predicting the outcomes of interferon（IFN）therapy in the patients with HBeAg positive chronic hepatitis B（CHB）.Methods Sixty-nine CHB patients with HBeAg positive were treated with IFN for 48 weeks.Serum levels of IL-21 were detected by ELISA before and in the 12^th,24^th,36 ^th,and 48 ^th week of IFN treatment.Serum level of HBV-M was detected by chemiluminescent micropartical immunoassay and that of HBV DNA was detected by fluorescence quantitative PCR.Results Of 69 patients,22 cases（31.9%）had complete response（group CR）to IFN therapy with HBeAg disapprearance,HBeAb apprearance and HBV DNA<500IU/ml.Another 47cases（68.1%）had no complete response（group NCR）.Serum level of IL-21 before treatment was significantly higher in group CR than that in group NCR（P<0.05）.Before treatment,66.7% of CR patients had serum IL-21levels≥110pg/ml and 80.0%of them had serum IL-21levels≥110pg/ml as well as HBsAg levels≤3.84log₁₀ IU/ml.Conclusion High expression of serum IL-21 predicts a better efficacy of IFN therapy in CHB patients with HBeAg positive.更多还原